Your browser doesn't support javascript.
loading
Clinical feasibility study of protrach dualcare a new speaking valve with heat and moisture exchanger for tracheotomized patients.
de Kleijn, B J; van As-Brooks, C J; Wedman, J; van der Laan, B F A M.
Afiliación
  • de Kleijn BJ; Department of Otorhinolaryngology-Head & Neck Surgery University of Groningen, University Medical Center Groningen Groningen the Netherlands.
  • van As-Brooks CJ; Department of Head and Neck Surgical Oncology Netherlands Cancer Institute Amsterdamthe Netherlands.
  • Wedman J; Department of Clinical Affairs Atos Medical AB Malmö Sweden.
  • van der Laan BFAM; Department of Otorhinolaryngology-Head & Neck Surgery University of Groningen, University Medical Center Groningen Groningen the Netherlands.
Laryngoscope Investig Otolaryngol ; 2(6): 453-458, 2017 12.
Article en En | MEDLINE | ID: mdl-29299523
Objective: The aim of this study was to evaluate the clinical feasibility of the ProTrach DualCare (Atos Medical, Hörby, Sweden), a device combining a hands-free speaking valve and a Heat and Moisture Exchanger (HME) for tracheotomized patients. Study Design: A non-randomized, prospective single center feasibility study. Methods: Sixteen adult tracheotomized patients were included. Participants were asked to test the DualCare for two weeks while continuing their normal activities. After these two weeks, participants could choose whether or not to take part in the long-term evaluation. The EuroQOL-5D, Borg scale and questionnaires on speaking, pulmonary function and patient preference were used. During the long-term evaluation, a minor redesign was implemented and all participants were asked to test the new device again for one week, with a potential long-term evaluation. Eleven decided to participate. Results: The device was well-tolerated. Speaking noise was reduced (p = 0.020) and speech was considered to sound more natural compared to previously used devices according to the users (p = 0.020). Overall 11 participants preferred the DualCare to their standard device. No serious adverse events were reported. Conclusion: Overall, 11 of 16 participants preferred the DualCare to their standard speaking valve or HME. Users of the DualCare were able to use hands free speech with the benefits of an HME and the device was considered clinically feasible and has the potential to improve quality of life of tracheotomized patients. Level of Evidence: 2b.
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Laryngoscope Investig Otolaryngol Año: 2017 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Laryngoscope Investig Otolaryngol Año: 2017 Tipo del documento: Article